Literature DB >> 29411223

In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.

Jason Krause1, Carminita L Frost2.   

Abstract

Cancer procoagulant (CP), a direct activator of coagulation factor X, is among one of the tumour cell products or activities which may promote fibrin formation and has been suggested to be selectively associated with the malignant phenotype. At present, the most reliable assay for the quantification of CP activity is the three-stage chromogenic assay which utilises the ability of CP to activate factor X. In this assay, the activation of factor X leads to the formation of activated thrombin from prothrombin and the eventual hydrolyses of a thrombin chromogenic substrate which contains a p-nitroaniline leaving group. The complexity of the three-stage chromogenic assay suggests a need for a direct method of assaying CP activity. This study focuses on the design of a fluorogenic substrate that would enable the direct quantification of CP activity. The results of the study show two promising substrates for the determination of CP activity: Boc-PQVR-AMC and PQVR-AMC. Further analysis showed that Boc-PQVR-AMC could be excluded as a potential substrate for CP since it was also cleaved by collagenase.

Entities:  

Keywords:  CP assay; Extracellular matrix; Factor X; Fibronectin; Kinetics; Peptide substrates

Mesh:

Substances:

Year:  2018        PMID: 29411223     DOI: 10.1007/s10930-018-9758-x

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  32 in total

1.  Cancer procoagulant activity studies using synthetic peptidyl substrates.

Authors:  W P Mielicki; E Mielicka; S G Gordon
Journal:  Thromb Res       Date:  1997-07-15       Impact factor: 3.944

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors.

Authors:  W P Mielicki; M Tagawa; S G Gordon
Journal:  Thromb Haemost       Date:  1994-04       Impact factor: 5.249

Review 4.  Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue.

Authors:  S G Gordon; W P Mielicki
Journal:  Blood Coagul Fibrinolysis       Date:  1997-03       Impact factor: 1.276

5.  The epidermal platelet-activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines.

Authors:  Tao Li; Michael D Southall; Qiaofang Yi; Yong Pei; Davina Lewis; Mohammed Al-Hassani; Dan Spandau; Jeffrey B Travers
Journal:  J Biol Chem       Date:  2003-02-24       Impact factor: 5.157

6.  The site of activation of factor X by cancer procoagulant.

Authors:  S G Gordon; A M Mourad
Journal:  Blood Coagul Fibrinolysis       Date:  1991-12       Impact factor: 1.276

7.  A factor X-activating cysteine protease from malignant tissue.

Authors:  S G Gordon; B A Cross
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

8.  A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin.

Authors:  R Pytela; M D Pierschbacher; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Prolyl aminopeptidase from rat brain and kidney. Action on peptides and identification as leucyl aminopeptidase.

Authors:  A Turzynski; R Mentlein
Journal:  Eur J Biochem       Date:  1990-07-05

10.  The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin.

Authors:  I F Charo; L Nannizzi; J W Smith; D A Cheresh
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.